1. Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction J Am Coll Cardiol. 1999;34(4):983-988. doi:10.1016/S0735-1097(99)00318-6 Serial changes in the serum levels of angiotensin-converting enzyme (ACE) activity in patients treated with enalapril and placebo (mean ± SEM). Solid circle = enalapril; open circle = placebo. ∗∗ p < 0.01 vs. before administration; ††p < 0.01 vs. placebo. Figure Legend:

2. Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction J Am Coll Cardiol. 1999;34(4):983-988. doi:10.1016/S0735-1097(99)00318-6 Serial changes in the plasma levels of tissue factor (TF) antigen in patients treated with enalapril and placebo (mean ± SEM). Solid circle = enalapril; open circle = placebo. ∗ p < 0.05 vs. before administration; ∗∗ p < 0.01 vs. before administration; ††p < 0.01 vs. placebo. Figure Legend:

3. Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction J Am Coll Cardiol. 1999;34(4):983-988. doi:10.1016/S0735-1097(99)00318-6 Serial changes in the plasma levels of free tissue factor pathway inhibitor (TFPI) antigen in patients treated with enalapril and placebo (mean ± SEM). Solid circle = enalapril; open circle = placebo. Figure Legend:

4. Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction J Am Coll Cardiol. 1999;34(4):983-988. doi:10.1016/S0735-1097(99)00318-6 Serial changes in the plasma levels of monocyte chemoattractant protein-1 (MCP-1) antigen in patients treated with enalapril and placebo (mean ± SEM). Solid circle = enalapril; open circle = placebo. ∗ p < 0.05 vs. before administration; ††p < 0.01 vs. placebo; †p < 0.05 vs. placebo. Figure Legend:

5. Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction J Am Coll Cardiol. 1999;34(4):983-988. doi:10.1016/S0735-1097(99)00318-6 The correlations between the serum angiotensin-converting enzyme (ACE) activity and plasma monocyte chemoattractant protein-1 (MCP-1) levels (A), the serum ACE activity and plasma tissue factor (TF) levels (B) and the MCP-1 and TF levels (C). Figure Legend: